pyrazines has been researched along with Colorectal Cancer in 48 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (12.50) | 18.2507 |
| 2000's | 13 (27.08) | 29.6817 |
| 2010's | 22 (45.83) | 24.3611 |
| 2020's | 7 (14.58) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Dong, Y; Gu, Y; He, J; Li, Y; Liang, H; Liu, C; Ou, J; Shen, K; Tan, J; Wang, H; Wang, L; Wang, Y; Wei, L; Wu, S; Xie, G; Zhang, C; Zhang, Y; Zhao, X; Zhao, Y; Zheng, W; Zhou, Q | 1 |
| Li, C; Liu, B; Liu, C; Ma, L; Qin, W; Qiu, H; Tu, J; Wang, X; Yuan, X; Zhao, W | 1 |
| Li, L; Li, M; Li, W; Lin, L | 1 |
| Chen, ZZ; Li, HY; Tan, HB; Tang, DY; Xu, J; Xu, ZG; Zhan, F; Zhang, YJ | 1 |
| Bian, Y; Li, W; Li, Z; Sheng, W; Xu, Y; Yang, L; Zeng, L | 1 |
| Markham, A | 1 |
| Amoreo, CA; Baiocchi, M; Barresi, S; Corradi, F; De Angelis, ML; De Luca, G; De Maria, R; De Nicola, F; Di Franco, S; Fanciulli, M; Manic, G; Maugeri-Saccà, M; Mottolese, M; Musella, M; Pallocca, M; Policicchio, E; Russo, G; Signore, M; Sistigu, A; Siteni, S; Sperati, F; Stassi, G; Tartaglia, M; Vitale, I; Vitale, S; Zeuner, A | 1 |
| Huang, Z; Ji, Y; Lai, Y; Liu, J; Tian, J; Xu, J; Yan, C; Zhang, Y; Zhao, D; Zou, Y | 1 |
| Bruens, L; Cammareri, P; Campbell, AD; Faller, WJ; Gay, DM; Hodder, MC; Huels, DJ; McLaughlin, ME; Morrissey, E; Nixon, C; Ridgway, RA; Sansom, OJ; Snippert, HJ; Solar-Abboud, M; van Rheenen, J; Winton, DJ; Zeiger, LB | 1 |
| Gong, JP; Hu, H; Hu, YB; Li, XL; Mi, YL; Mu, L; Qin, JC; Tao, DD; Wu, YQ; Yan, C; Zhao, H | 1 |
| Andrade, AF; Beijersbergen, RL; Bonnefoy, N; Combès, E; Coquel, F; Coquelle, A; Del Rio, M; Desigaud, D; Garambois, V; Gongora, C; Jarlier, M; Martineau, P; Michaud, HA; Moreaux, J; Pasero, P; Tosi, D; Vezzio-Vie, N | 1 |
| Bagheri, M; Ghasemi, F; Mirzaei, H; Tabatabae Far, MA | 1 |
| Clevers, H; Joosten, SPJ; Mizutani, T; Pals, ST; Spaargaren, M | 1 |
| Cassidy, J; Hochster, H | 1 |
| Borst, G; Clayton, J; Collins, I; Federspiel, MJ; Garrett, M; Harrington, KJ; Karapanagiotou, EM; Khan, AA; Kyula, J; Mansfield, D; McLaughlin, M; Pencavel, T; Roulstone, V; Russell, SJ; Touchefeu, Y; Zaidi, SH | 1 |
| Eckhardt, SG; Flanigan, SA; Kachaeva, MI; Kulikowski, GN; Leong, S; McManus, MC; Newton, TP; Pitts, TM; Selby, HM; Spreafico, A; Tan, AC; Tentler, JJ | 1 |
| Agarwal, E; Brattain, MG; Chowdhury, S; Haferbier, KL; Leiphrakpam, PD; Mathiesen, M | 1 |
| Chen, ZR; Huang, M; Min, H; Xu, M; Zheng, K; Zhou, JD; Zou, XP | 1 |
| Barton, J; Bendell, JC; Burris, HA; Earwood, C; Hart, L; Infante, JR; Jones, SF; Lane, CM; Spigel, DR | 1 |
| Bittner, S; Ehrenschwender, M; Seibold, K; Wajant, H | 1 |
| Chen, L; Wang, Q; Yang, HS; Zhang, Y | 1 |
| Baryawno, N; Calero, R; Darabi, A; Dyberg, C; Einvik, C; Johnsen, JI; Kogner, P; Kool, M; Milosevic, J; Sandén, E; Siesjö, P; Sveinbjörnsson, B; Wickström, M | 1 |
| Massey, AJ | 1 |
| Acquaviva, A; Bardelli, A; Centonze, A; Crisafulli, G; Medico, E; Novara, L; Petti, C; Picco, G; Torchiaro, E | 1 |
| Anthoney, A; Bauer, J; Caponigro, F; Govaerts, AS; Lacombe, D; Marréaud, S; Milano, A; Twelves, C | 1 |
| Cao, X; Garofalo, A; Grande, F; Louie, S; Neamati, N; Oshima, T; Yamada, R | 1 |
| Alakus, H; Auer, T; Gamerith, G; Hilbe, W; Krugmann, J; Lindner, H; Loeffler-Ragg, J; Martin, HJ; Maser, E; Menzel, J; Mueller, D; Sarg, B; Schmid, KW; Schmitz, KJ; Skvortsov, S; Skvortsova, I; Zwierzina, H | 1 |
| Hatzidaki, E; Karagiannaki, A; Papandreou, CN; Patrikidou, A; Stathakis, NE; Tsapakidis, K; Voutsadakis, IA | 1 |
| Eckhardt, SG; Flanigan, SA; Leong, S; Pitts, TM; Tan, AC; Tentler, JJ; Thorburn, A | 1 |
| Nicholson, B; Suresh Kumar, KG | 1 |
| Abduljabbar, A; Abubaker, J; Ahmed, M; Al-Dayel, F; Al-Kuraya, KS; Al-Sanea, N; Alhomoud, S; Ashari, LH; Bavi, P; Bu, R; Hussain, AR; Jehan, Z; Prabhakaran, S; Sultana, M; Uddin, S | 1 |
| Stockler, MR; Wilcken, NR | 1 |
| Anderson, KC; Eng, C; Hideshima, T; Kolesar, J; Richardson, PG | 1 |
| Birle, D; Degendorfer, P; Hedley, D; Mackay, H; Mackenzie, M; Major, P; Moore, M; Nicklee, T; Oza, A; Siu, L; Townsley, C; Tsao, MS; Vincent, M; Wright, J | 1 |
| Arnold, LD; Buck, E; Cooke, A; Eyzaguirre, A; Feng, L; Gibson, NW; Ji, QS; Mak, G; Mulvihill, MJ; O'Connor, M; Pachter, JA; Pirritt, C; Rosenfeld-Franklin, M; Yao, Y | 1 |
| AbdulJabbar, A; Ahmed, M; Al-Dayel, F; Al-Kuraya, KS; Al-Sanea, N; Alhomoud, S; Ashari, LH; Bavi, P; El-Sayed, R; Hussain, AR; Uddin, S | 1 |
| Atiq, OT; Dragovich, T; Hochster, H; Kozuch, PS; Lenz, HJ; O'Neil, BH; Pipas, JM; Rocha-Lima, CM; Ryan, DP | 1 |
| Balshem, AM; Brennan, J; Clapper, ML; Engstrom, PF; Frucht, H; Gallo, JM; Goosenberg, EB; Green, F; Halbherr, TC; Hamilton, TC; Litwin, S; O'Dwyer, PJ; Pfeiffer, GR; Szarka, CE; Yao, KS | 1 |
| Brenner, DE; Krishnan, K | 1 |
| Abbruzzese, JL; Ajani, J; Diaz-Canton, E; Grove, W; Meyers, C; Patt, Y; Pazdur, R | 1 |
| Ansari, RH; Brockstein, BE; Garcia, JC; Mani, S; Meyer, SC; Mick, R; Ratain, MJ; Rhinehart, SN; Schilsky, RL; Stadler, WM; Taber, D; Vogelzang, NJ; Vokes, EE | 1 |
| Clapper, ML; Szarka, CE | 1 |
| Conrad, CA; Gelke, CK; Grove, W; Kudelka, AP; Meyers, CA; Pazdur, R | 1 |
| Brenner, DE; Krishnan, K; Ruffin, MT | 1 |
| Brennan, JM; Gallo, JM; Laub, PB; O'Dwyer, PJ; Szarka, C | 1 |
| Adams, J; Baldwin, AS; Cusack, JC; Elliott, P; Liu, R; Russo, SM; Tepper, JE | 1 |
| Abendroth, K; Adams, J; Baldwin, AS; Cusack, JC; Elliott, PJ; Houston, M; Liu, R | 1 |
| Balshem, AM; Clapper, ML; Engstrom, PF; Frucht, H; Goosenberg, EB; Litwin, S; O'Dwyer, PJ; Pfeiffer, GR; Szarka, CE; Yao, KS | 1 |
6 review(s) available for pyrazines and Colorectal Cancer
| Article | Year |
|---|---|
Savolitinib: First Approval.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; China; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Drug Approval; Humans; Kidney Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Pyrazines; Stomach Neoplasms; Triazines | 2021 |
New oxaliplatin-based combinations in the treatment of colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gefitinib; Humans; Irinotecan; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Pyrazines; Quinazolines; Thiophenes | 2003 |
The multifaceted roles of USP7: new therapeutic opportunities.
Topics: Apoptosis; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Drug Screening Assays, Antitumor; HCT116 Cells; Humans; Indenes; Protease Inhibitors; Pyrazines; Tumor Suppressor Protein p53; Ubiquitin Thiolesterase; Ubiquitin-Specific Peptidase 7 | 2011 |
Chemoprevention of colorectal cancer.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antioxidants; Calcium; Colorectal Neoplasms; Eflornithine; Ellagic Acid; Humans; Pyrazines; Thiones; Thiophenes | 1996 |
Glutathione S-transferases--biomarkers of cancer risk and chemopreventive response.
Topics: Animals; Anticarcinogenic Agents; Biomarkers; Brassica; Colitis, Ulcerative; Colorectal Neoplasms; Disease Models, Animal; Enzyme Induction; Gene Expression; Glutathione Transferase; Humans; Inactivation, Metabolic; Mice; Neoplasms; Pyrazines; Risk Factors; Thiones; Thiophenes | 1998 |
Chemoprevention for colorectal cancer.
Topics: Adenoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antioxidants; Apoptosis; Arachidonic Acids; Bile Acids and Salts; Biomarkers; Calcium; Cell Cycle; Cell Transformation, Neoplastic; Clinical Trials as Topic; Colonic Polyps; Colorectal Neoplasms; DNA Methylation; DNA Repair; Eflornithine; Enzyme Inhibitors; Estrogens; Free Radical Scavengers; Genetic Predisposition to Disease; Humans; Mice; Ornithine Decarboxylase Inhibitors; Patient Compliance; Patient Selection; Polyamines; Precancerous Conditions; Pyrazines; Rats; Retinoids; Thiones; Thiophenes; Tumor Cells, Cultured; Vitamins | 2000 |
10 trial(s) available for pyrazines and Colorectal Cancer
| Article | Year |
|---|---|
A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Everolimus; Female; Humans; Imidazoles; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase Inhibitors; Pyrazines; Receptor, IGF Type 1; Sirolimus | 2015 |
An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Colorectal Neoplasms; Disease-Free Survival; DNA Repair; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Pyrazines; Survival Rate | 2009 |
A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents; Biopsy; Boronic Acids; Bortezomib; Carbonic Anhydrase IX; Carbonic Anhydrases; Colorectal Neoplasms; Disease Progression; Enzyme Inhibitors; Female; Humans; Immunohistochemistry; Infusions, Intravenous; Liver; Male; Microcirculation; Middle Aged; Neoplasm Metastasis; Neoplasm Transplantation; NF-kappa B; Phosphorylation; Proteasome Inhibitors; Pyrazines; Serine; Time Factors; Treatment Outcome; Tumor Suppressor Protein p53 | 2005 |
Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Pyrazines; Survival Rate | 2008 |
Modulation of gene expression in subjects at risk for colorectal cancer by the chemopreventive dithiolethione oltipraz.
Topics: Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Chemoprevention; Colon; Colorectal Neoplasms; Female; Gene Expression Regulation, Neoplastic; Glutamate-Cysteine Ligase; Humans; Inactivation, Metabolic; Intestinal Mucosa; Leukocytes, Mononuclear; Male; Middle Aged; Mutagenesis; NAD(P)H Dehydrogenase (Quinone); Pyrazines; Risk; Thiones; Thiophenes | 1996 |
Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carbamates; Central Nervous System Diseases; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Prospective Studies; Pyrazines; Pyridines | 1997 |
Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Count; Colorectal Neoplasms; Female; Humans; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Pyrazines; Survival Rate | 1998 |
Neurotoxicity of CI-980, a novel mitotic inhibitor.
Topics: Adult; Aged; Antineoplastic Agents; Carbamates; Cognition; Cognition Disorders; Colorectal Neoplasms; Female; Humans; Male; Memory; Memory Disorders; Middle Aged; Neuropsychological Tests; Neurotoxins; Ovarian Neoplasms; Pyrazines; Pyridines | 1997 |
Pharmacokinetics of the chemopreventive agent oltipraz and of its metabolite M3 in human subjects after a single oral dose.
Topics: Administration, Oral; Anticarcinogenic Agents; Area Under Curve; Calibration; Chromatography, High Pressure Liquid; Colonic Polyps; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Kinetics; Male; Pyrazines; Risk Factors; Thiones; Thiophenes; Time Factors | 2000 |
Chronic dosing of oltipraz in people at increased risk for colorectal cancer.
Topics: Aged; Aged, 80 and over; Anticarcinogenic Agents; Biomarkers, Tumor; Colorectal Neoplasms; Enzyme Induction; Female; Glutathione; Glutathione Transferase; Humans; Male; Middle Aged; NAD(P)H Dehydrogenase (Quinone); Pyrazines; Thiones; Thiophenes | 2001 |
32 other study(ies) available for pyrazines and Colorectal Cancer
| Article | Year |
|---|---|
ABHD5 inhibits YAP-induced c-Met overexpression and colon cancer cell stemness via suppressing YAP methylation.
Topics: 1-Acylglycerol-3-Phosphate O-Acyltransferase; Animals; Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplasms; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Male; Methylation; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Neoplastic Stem Cells; Proto-Oncogene Proteins c-met; Pyrazines; Triazines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2021 |
Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Colorectal Neoplasms; Humans; Immunotherapy; Mice; Pyrazines; Tumor Microenvironment | 2023 |
Gilteritinib induces PUMA-dependent apoptotic cell death via AKT/GSK-3β/NF-κB pathway in colorectal cancer cells.
Topics: Aniline Compounds; Animals; Apoptosis; Apoptosis Regulatory Proteins; Cell Death; Cell Line; Cell Line, Tumor; Colorectal Neoplasms; Female; Glycogen Synthase Kinase 3 beta; HCT116 Cells; HEK293 Cells; Humans; Mice; Mice, Nude; NF-kappa B; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction; Xenograft Model Antitumor Assays | 2020 |
Catalyst-Free One-Pot Synthesis of Densely Substituted Pyrazole-Pyrazines as Anti-Colorectal Cancer Agents.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; G2 Phase Cell Cycle Checkpoints; HCT116 Cells; Humans; Pyrazines; Pyrazoles; Structure-Activity Relationship | 2020 |
Ligustrazine induces the colorectal cancer cells apoptosis via p53-dependent mitochondrial pathway and cell cycle arrest at the G0/G1 phase.
Topics: Apoptosis; Cell Cycle Checkpoints; Cell Proliferation; Colorectal Neoplasms; G1 Phase; Humans; Pyrazines; Signal Transduction; Tumor Suppressor Protein p53 | 2021 |
CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Checkpoint Kinase 1; Colorectal Neoplasms; DNA Replication; Humans; Immunohistochemistry; Mutation; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Pyrazines; Pyrazoles; Tumor Suppressor Protein p53 | 2018 |
Novel Ligustrazine-Based Analogs of Piperlongumine Potently Suppress Proliferation and Metastasis of Colorectal Cancer Cells in Vitro and in Vivo.
Topics: Animals; Antineoplastic Agents; beta Catenin; Cell Proliferation; Colorectal Neoplasms; Dioxolanes; Epithelial-Mesenchymal Transition; HCT116 Cells; Humans; Mice; Neoplasm Metastasis; Pyrazines; Reactive Oxygen Species; Solubility; Structure-Activity Relationship | 2018 |
Wnt ligands influence tumour initiation by controlling the number of intestinal stem cells.
Topics: Acyltransferases; Adenoma; Adenomatous Polyposis Coli Protein; Animals; Carcinogenesis; Cell Transformation, Neoplastic; Colorectal Neoplasms; Enzyme Inhibitors; Intestinal Mucosa; Ligands; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pyrazines; Pyridines; Stem Cells; Wnt Signaling Pathway | 2018 |
Exosomal Wnt-induced dedifferentiation of colorectal cancer cells contributes to chemotherapy resistance.
Topics: Animals; Antineoplastic Agents; Cell Dedifferentiation; Cell Proliferation; Cells, Cultured; Colorectal Neoplasms; Drug Resistance, Neoplasm; Exosomes; Female; Fibroblasts; Fluorouracil; HT29 Cells; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Oxaliplatin; Paracrine Communication; Pyrazines; Pyridines; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2019 |
Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Line, Tumor; Checkpoint Kinase 2; Colorectal Neoplasms; DNA Breaks, Double-Stranded; Drug Resistance, Neoplasm; Female; Humans; Isoxazoles; Mice, Inbred C57BL; Oxaliplatin; Pyrazines; T-Lymphocytes; Xenograft Model Antitumor Assays | 2019 |
Evaluation of antitumor effects of aspirin and LGK974 drugs on cellular signaling pathways, cell cycle and apoptosis in colorectal cancer cell lines compared to oxaliplatin drug.
Topics: Antineoplastic Agents; Apoptosis; Aspirin; Cell Cycle; Cell Line, Tumor; Colorectal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; MAP Kinase Signaling System; Oxaliplatin; Pyrazines; Pyridines; Wnt Signaling Pathway | 2020 |
MET Signaling Overcomes Epidermal Growth Factor Receptor Inhibition in Normal and Colorectal Cancer Stem Cells Causing Drug Resistance.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genes, APC; Humans; Intestinal Mucosa; Mutation; Neoplastic Stem Cells; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazines; Signal Transduction; Triazines | 2019 |
Optimising measles virus-guided radiovirotherapy with external beam radiotherapy and specific checkpoint kinase 1 inhibition.
Topics: Animals; Cell Line, Tumor; Checkpoint Kinase 1; Colorectal Neoplasms; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Iodine Radioisotopes; Isoquinolines; Measles virus; Mice; Oncolytic Virotherapy; Protein Kinase Inhibitors; Protein Kinases; Pyrazines; Radiation-Sensitizing Agents; Symporters; Virus Replication; Xenograft Model Antitumor Assays | 2013 |
Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Butadienes; Caspase 3; Caspase 7; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Imidazoles; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mice; Mice, Nude; Neoplasm Transplantation; Nitriles; Protein Kinase Inhibitors; Pyrazines; Receptor, IGF Type 1; Receptor, Insulin; Signal Transduction; Transplantation, Heterologous | 2013 |
In vivo analysis of insulin-like growth factor type 1 receptor humanized monoclonal antibody MK-0646 and small molecule kinase inhibitor OSI-906 in colorectal cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Down-Regulation; Humans; Imidazoles; Male; Mice; Mice, Nude; Neoplasm Transplantation; Pyrazines; Receptor, IGF Type 1; Signal Transduction; X-Linked Inhibitor of Apoptosis Protein; Xenograft Model Antitumor Assays | 2014 |
Bortezomib induces protective autophagy through AMP-activated protein kinase activation in cultured pancreatic and colorectal cancer cells.
Topics: Adenine; AMP-Activated Protein Kinases; Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Cell Survival; Cells, Cultured; Chloroquine; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Humans; Neoplasm Proteins; Pancreatic Neoplasms; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines; RNA Interference; RNA, Small Interfering | 2014 |
XIAP-targeting drugs re-sensitize PIK3CA-mutated colorectal cancer cells for death receptor-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Drug Resistance, Neoplasm; Humans; Mutation; Phosphatidylinositol 3-Kinases; Pyrazines; Receptors, Death Domain; TNF-Related Apoptosis-Inducing Ligand; X-Linked Inhibitor of Apoptosis Protein | 2014 |
Inhibition of p70S6K1 Activation by Pdcd4 Overcomes the Resistance to an IGF-1R/IR Inhibitor in Colon Carcinoma Cells.
Topics: Animals; Apoptosis Regulatory Proteins; Caco-2 Cells; Carcinoma; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; HCT116 Cells; HT29 Cells; Humans; Imidazoles; Mice; Mice, Nude; Piperazines; Protein Kinase Inhibitors; Pyrazines; Receptor, IGF Type 1; Ribosomal Protein S6 Kinases, 70-kDa; RNA-Binding Proteins; Xenograft Model Antitumor Assays | 2015 |
Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance.
Topics: Animals; Antineoplastic Agents; Benzeneacetamides; beta Catenin; Brain Neoplasms; Camptothecin; Celecoxib; Cisplatin; Colorectal Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Doxorubicin; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioma; Glucose-6-Phosphate Isomerase; Heterocyclic Compounds, 3-Ring; Humans; Immunoblotting; Immunohistochemistry; Irinotecan; Medulloblastoma; Mice; Neoplasm Transplantation; Neoplasms; Neuroblastoma; Pyrans; Pyrazines; Pyridines; Real-Time Polymerase Chain Reaction; Sulfones; Temozolomide; Triazoles; Tumor Suppressor Proteins; Vincristine; Wnt Proteins; Wnt Signaling Pathway | 2015 |
Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Bone Neoplasms; Cell Proliferation; Checkpoint Kinase 1; Colorectal Neoplasms; DNA Damage; DNA-Activated Protein Kinase; Dose-Response Relationship, Drug; Histones; HT29 Cells; Humans; Indoles; Isoxazoles; Molecular Targeted Therapy; Nuclear Proteins; Osteosarcoma; Protein Kinase Inhibitors; Pyrazines; Pyridones; Signal Transduction; Time Factors | 2016 |
Loss of AXIN1 drives acquired resistance to WNT pathway blockade in colorectal cancer cells carrying RSPO3 fusions.
Topics: Axin Protein; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance; Enzyme Inhibitors; Gene Fusion; Humans; Pyrazines; Pyridines; Thrombospondins; Wnt Proteins; Wnt Signaling Pathway | 2017 |
Combination effects of SC144 and cytotoxic anticancer agents.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Cytotoxins; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Inhibitory Concentration 50; Injections, Intraperitoneal; Mice; Mice, Nude; Organoplatinum Compounds; Paclitaxel; Pyrazines; Quinoxalines; Xenograft Model Antitumor Assays | 2009 |
Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib.
Topics: Aldehyde Reductase; Aldo-Keto Reductases; Biomarkers, Tumor; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cohort Studies; Colorectal Neoplasms; Cyclooxygenase 2; Electrophoresis, Gel, Two-Dimensional; HSP72 Heat-Shock Proteins; Humans; Phosphorylation; Protease Inhibitors; Proteome; Proto-Oncogene Proteins c-akt; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Survival Rate; Tissue Array Analysis; Tumor Cells, Cultured | 2009 |
Additive inhibition of colorectal cancer cell lines by aspirin and bortezomib.
Topics: Apoptosis; Aspirin; bcl-Associated Death Protein; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclooxygenase 2; Down-Regulation; Drug Synergism; Humans; NF-kappa B; Proto-Oncogene Proteins c-akt; Pyrazines | 2010 |
The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Proliferation; Colorectal Neoplasms; Drug Combinations; Drug Screening Assays, Antitumor; Female; Humans; Imidazoles; Mice; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Receptor, IGF Type 1; Structure-Activity Relationship; Tumor Cells, Cultured | 2010 |
Bortezomib stabilizes mitotic cyclins and prevents cell cycle progression via inhibition of UBE2C in colorectal carcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Cycle; Colorectal Neoplasms; Cyclins; Gene Dosage; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Mice; Mice, Nude; Prognosis; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Tissue Array Analysis; Ubiquitin-Conjugating Enzymes; Xenograft Model Antitumor Assays | 2011 |
Why is management of cancer pain still a problem?
Topics: Analgesics; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Colorectal Neoplasms; Female; Healthcare Disparities; Humans; Lung Neoplasms; Male; Multiple Myeloma; Pain Management; Practice Patterns, Physicians'; Prostatic Neoplasms; Pyrazines | 2012 |
Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Capecitabine; Cell Line, Tumor; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Dexamethasone; Drug Evaluation, Preclinical; Fluorouracil; Humans; Multiple Myeloma; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Pyrazines; Randomized Controlled Trials as Topic | 2012 |
A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo.
Topics: Animals; Antineoplastic Agents; Autocrine Communication; Blood Glucose; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Enzyme Activation; Female; Humans; Imidazoles; Insulin-Like Growth Factor II; Mice; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Pyrazines; Receptor, IGF Type 1; Signal Transduction; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2007 |
Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p27; Female; Humans; Male; Mice; Mice, Nude; Middle Aged; Protease Inhibitors; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; S-Phase Kinase-Associated Proteins; Tissue Array Analysis; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.
Topics: Adenoviridae; Animals; Apoptosis; Boronic Acids; Bortezomib; Colorectal Neoplasms; Cysteine Endopeptidases; DNA-Binding Proteins; Female; Humans; I-kappa B Proteins; Mice; Mice, Nude; Multienzyme Complexes; NF-kappa B; NF-KappaB Inhibitor alpha; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Radiation Tolerance; Radiation-Sensitizing Agents; Repressor Proteins; Transduction, Genetic; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Camptothecin; Colorectal Neoplasms; Cysteine Endopeptidases; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Female; Humans; Irinotecan; Mice; Mice, Nude; Multienzyme Complexes; NF-kappa B; Proteasome Endopeptidase Complex; Pyrazines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |